PMID- 1555692
OWN - NLM
STAT- MEDLINE
DCOM- 19920501
LR  - 20190707
IS  - 0015-0282 (Print)
IS  - 0015-0282 (Linking)
VI  - 57
IP  - 4
DP  - 1992 Apr
TI  - The long protocol of administration of gonadotropin-releasing hormone agonist is 
      superior to the short protocol for ovarian stimulation for in vitro 
      fertilization.
PG  - 810-4
AB  - OBJECTIVE: To investigate whether pituitary desensitization with the 
      gonadotropin-releasing hormone agonist (GnRH-a), buserelin acetate, before the 
      administration of human menopausal gonadotropin (hMG) for ovarian stimulation in 
      in vitro fertilization (IVF) is superior to the simultaneous administration of 
      both hormones at the beginning of the treatment cycle. DESIGN: Prospective 
      randomized study. PATIENTS: Ninety-one patients having their first attempt at 
      IVF. INTERVENTIONS: Patients in group 1 (long protocol) were administered 
      subcutaneous (SC) buserelin acetate 200 micrograms/d from day 1 of the menstrual 
      cycle, and hMG was started only after pituitary desensitization had been achieved 
      at least 14 days later. Patients in group 2 (short protocol) were administered SC 
      buserelin acetate 200 micrograms/d from day 2 and the same dose of hMG used in 
      the long protocol from day 3 of the menstrual cycle. RESULTS: The median total 
      amount of hMG required in both groups was comparable. There were significantly 
      more follicles (P = 0.0001), oocytes (P = 0.0008), fertilized oocytes (P = 
      0.0001), and cleaved embryos (P = 0.0001), and a higher fertilization rate (P = 
      0.0047) in patients in group 1. The pregnancy rates per initiated cycle and per 
      embryo transfer were 19.57% and 25.71% in group 1 compared with 8.89% and 16.67% 
      in group 2. CONCLUSIONS: The long protocol is superior in terms of significantly 
      greater follicular recruitment, oocyte recovery and fertilization rates, and 
      significantly greater number of embryos available for transfer. In general, it is 
      the preferred method when GnRH-a are used for ovarian stimulation in IVF.
FAU - Tan, S L
AU  - Tan SL
AD  - Hallam Medical Centre, London, United Kingdom.
FAU - Kingsland, C
AU  - Kingsland C
FAU - Campbell, S
AU  - Campbell S
FAU - Mills, C
AU  - Mills C
FAU - Bradfield, J
AU  - Bradfield J
FAU - Alexander, N
AU  - Alexander N
FAU - Yovich, J
AU  - Yovich J
FAU - Jacobs, H S
AU  - Jacobs HS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - 0 (Delayed-Action Preparations)
RN  - 08AN7WA2G0 (Triptorelin Pamoate)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
RN  - 57773-65-6 (Tryptal)
SB  - IM
MH  - Adult
MH  - Delayed-Action Preparations
MH  - Drug Administration Schedule
MH  - Female
MH  - *Fertilization in Vitro
MH  - Gonadotropin-Releasing Hormone/administration & dosage/*analogs & 
      derivatives/therapeutic use
MH  - Humans
MH  - Infertility, Female
MH  - Infertility, Male
MH  - Male
MH  - Probability
MH  - Prospective Studies
MH  - *Triptorelin Pamoate/*analogs & derivatives
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
AID - S0015-0282(16)54963-2 [pii]
AID - 10.1016/s0015-0282(16)54963-2 [doi]
PST - ppublish
SO  - Fertil Steril. 1992 Apr;57(4):810-4. doi: 10.1016/s0015-0282(16)54963-2.